A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase (Q44381059)

2 December 2017

title

A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase (English)

1 reference

2 December 2017

1 reference

1 reference

1 reference

Chee-Kin Hui

1

1 reference

2 December 2017

Tigist Belaye

series ordinal

2

1 reference

2 December 2017

Kevin Montegrande

series ordinal

3

1 reference

2 December 2017

Teresa Lyn Wright

series ordinal

4

1 reference

2 December 2017

publication date

1 April 2003

1 reference

2 December 2017

published in

Journal of Hepatology

1 reference

2 December 2017

volume

38

1 reference

2 December 2017

issue

4

1 reference

2 December 2017

page(s)

511-517

1 reference

Epidemiology of Hepatitis C in the West

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900004-7

7 January 2021

A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900004-7

7 January 2021

Natural history of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900004-7

7 January 2021

Hepatitis C in asymptomatic blood donors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900004-7

7 January 2021

Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900004-7

7 January 2021

Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900004-7

7 January 2021

Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900004-7

7 January 2021

Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900004-7

7 January 2021

Hepatitis C virus RNA in serum and liver histology in asymptomatic anti-HCV positive subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900004-7

7 January 2021

Persistent hepatitis C viraemia without liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900004-7

7 January 2021

Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900004-7

7 January 2021

Liver biopsy in the evaluation of patients with chronic hepatitis C who have repeatedly normal or near-normal serum alanine aminotransferase levels

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900004-7

7 January 2021

Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900004-7

7 January 2021

Is severe liver disease a common outcome for people with chronic hepatitis C?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900004-7

7 January 2021

Estimating progression to cirrhosis in chronic hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900004-7

7 January 2021

Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900004-7

7 January 2021

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900004-7

7 January 2021

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900004-7

7 January 2021

Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900004-7

7 January 2021

Therapy of hepatitis C: patients with normal aminotransferase levels

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900004-7

7 January 2021

Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900004-7

7 January 2021

Is the natural history of hepatitis C virus carriers with normal aminotransferase really benign?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900004-7

7 January 2021

Intrahepatic hepatitis C RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900004-7

7 January 2021

Hepatitis C virus RNA profiles in chronically infected individuals: do they relate to disease activity?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900004-7

7 January 2021

10.1016/S0168-8278(03)00004-7

Identifiers

DOI

1 reference

2 December 2017

1 reference